# Combined Weight Review: APLLTD.NS

- **As of:** 2025-11-11
- **Assigned Weight:** 13.04%
- **News Lookback:** 7 day(s)

## Unified Summary
- Current allocation for APLLTD.NS stands at 13.04%; below are the latest fundamentals pulled from Yahoo Finance.
- Headline sentiment score: 2 (3 positive / 1 negative) alongside a 13.0% allocation.
- Profit Margin registered at 8.96% in the most recent filings.
- Return on Equity registered at 12.38% in the most recent filings.
- Revenue Growth registered at 15.90% in the most recent filings.
- News tone snapshot: 3 positive, 1 negative, 0 neutral items in the sample.
## Fundamental Agent Detail
- **As of:** 2025-11-11
- **Assigned Weight:** 13.04%

## Why This Weight
- Current allocation for APLLTD.NS stands at 13.04%; below are the latest fundamentals pulled from Yahoo Finance.
- Profit Margin registered at 8.96% in the most recent filings.
- Return on Equity registered at 12.38% in the most recent filings.
- Revenue Growth registered at 15.90% in the most recent filings.

## News Agent Detail
- **As of:** 2025-11-11
- **Assigned Weight:** 13.04%
- **News Lookback:** 7 day(s)

## Coverage Assessment
- Headline sentiment score: 2 (3 positive / 1 negative) alongside a 13.0% allocation.
- News tone snapshot: 3 positive, 1 negative, 0 neutral items in the sample.
- Positive headline from vendor (2025-11-11T03:38:50+00:00): Is Alembic Pharmaceuticals Limited Stock Set to Outperform Its Peers in YEAR - Stochastic Oscillator Alerts & Free Discover Fast Growing Stocks - earlytimes.in
- Positive headline from vendor (2025-11-10T12:33:38+00:00): Alembic Pharmaceuticals Limited announces USFDA Final Approval for Sumatriptan Injection - Konexio Network
